Ülevaade
Aktsiahinna muutus
24h
Praegune
Min
238.59
Max
243.9
Sissetulek | -100M 193M |
|---|---|
Müük | 139M 1.2B |
P/E Sektori keskmine | 16.893 56.597 |
Aktsiakasum | 4.89 |
Kasumimarginaal | 15.956 |
Töötajad | 2,890 |
EBITDA | -126M 418M |
Järgmine tulemuste avaldamine | 4. nov 2026 |
|---|
Turukapital | 138M 16B |
|---|---|
Eelmine avamishind | 239.98 |
Eelmine sulgemishind | 239.85 |
Uudiste sentiment
By Acuity
50%
50%
146 / 339 Pingereas Healthcare
Jazz Pharmaceuticals PLC Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
8. sept 2026, 20:03 UTC
Jazz Pharmaceuticals PLC is declining amid broader pharmaceuticals sector weakness, breaking a recent trend of higher daily closes since Friday.
Loe
4. sept 2026, 19:36 UTC
Jazz Pharmaceuticals PLC shares are lower today amid rising Treasury yields and strong labor market data, reflecting broader market trends.
Loe
3. sept 2026, 21:21 UTC
Jazz Pharmaceuticals PLC shares are lower in after-market hours, reflecting ongoing pressure despite broader market strength and decreasing rate hike expectations.
Loe
2. sept 2026, 19:46 UTC
Jazz Pharmaceuticals PLC shares are higher today, despite an earlier pullback. Broader market conditions include rising U.S. Treasury yields amid inflation concerns.
Loe
1. sept 2026, 19:54 UTC
Jazz Pharmaceuticals shares are lower despite positive Phase 3 trial results for Ziihera, influenced by tightening monetary policy expectations and rising Treasury yields.
Loe
31. aug 2026, 23:41 UTC
Jazz Pharmaceuticals PLC reported positive results from the HERIZON-GEA-01 trial for Ziihera, leading shares higher in after-hours trading.
Loe
28. aug 2026, 20:02 UTC
Jazz Pharmaceuticals PLC shares are lower today, reversing a trend of higher closes. Broader market pressures include rising U.S. Treasury yields amid inflation concerns.
Loe
26. aug 2026, 20:08 UTC
Jazz Pharmaceuticals PLC shares are lower following a $1 billion note offering and potential $225 million buyback, despite positive FDA approvals and target raises from analysts.
Loe
25. aug 2026, 20:07 UTC
Jazz Pharmaceuticals rises on FDA approval of Ziihera for treating advanced HER2-positive gastroesophageal cancer. Bank of America sets price target at $307.
Loe
24. aug 2026, 19:26 UTC
Jazz Pharmaceuticals shares are lower amid broader market sentiment influenced by geopolitical tensions. Ziihera's potential in the HER2+ market presents a growth opportunity.
Loe
22. aug 2026, 00:02 UTC
Jazz Pharmaceuticals PLC shares are lower in after-market hours, continuing a decline since Friday's close, despite broader gains in major U.S. stocks.
Loe
21. aug 2026, 20:06 UTC
Jazz Pharmaceuticals PLC shares are higher during Friday's session, reflecting strong upward momentum since Thursday's close, despite a recent pullback from session highs.
Loe
20. aug 2026, 19:56 UTC
Jazz Pharmaceuticals PLC shares are lower amid a broader market decline following disappointing sales growth and guidance from Walmart. They remain below their 20-day moving average.
Loe
19. aug 2026, 22:36 UTC
Jazz Pharmaceuticals PLC shares are lower in after-market hours, continuing a decline from regular trading, despite a broader recovery in equities.
Loe
18. aug 2026, 20:03 UTC
Jazz Pharmaceuticals shares are trading higher, reflecting strength in the pharmaceuticals sector, despite a slight pullback from earlier session gains.
Loe
17. aug 2026, 23:31 UTC
Jazz Pharmaceuticals PLC shares declined during after-market hours, reflecting broader market pressures from rising crude oil prices amid escalating U.S.-Iran tensions.
Loe
12. aug 2026, 19:46 UTC
Jazz Pharmaceuticals shares are higher after Q2 revenue rose 16% to $1.21 billion, exceeding expectations. The company raised its full-year guidance to $4.68 billion.
Loe
11. aug 2026, 22:46 UTC
Jazz Pharmaceuticals PLC shares advanced in after-market trading, diverging from broader market trends that closed lower amid rising crude oil prices.
Loe
10. aug 2026, 19:56 UTC
Jazz Pharmaceuticals PLC to acquire Actio Biosciences for $820 million, enhancing its rare epilepsy portfolio. Shares are higher despite earlier session pullback.
Loe
7. aug 2026, 19:36 UTC
Jazz Pharmaceuticals shares are higher today, reflecting broader market gains amid expectations the Federal Reserve may pause interest rate hikes.
Loe
6. aug 2026, 19:21 UTC
Jazz Pharmaceuticals PLC shares are lower today, despite earlier gains. Mixed economic signals contribute to cautious sentiment ahead of the non-farm payrolls report.
Loe
5. aug 2026, 19:36 UTC
Shares of Jazz Pharmaceuticals PLC are lower today, despite earlier gains. The company raised its full-year revenue guidance, driven by strong performance from Xywav.
Loe
4. aug 2026, 20:04 UTC
Jazz Pharmaceuticals PLC shares rise as analysts upgrade price targets, following strong Q2 results that beat revenue estimates and boosted 2026 sales guidance.
Loe
3. aug 2026, 23:02 UTC
Jazz Pharmaceuticals reported Q2 revenues of $1.208 billion, exceeding expectations. Shares advanced in after-market trading following the raised full-year guidance.
Loe
31. juuli 2026, 23:21 UTC
Jazz Pharmaceuticals PLC shares are lower in after-market trading, pulled back from earlier session highs amid broader market declines, particularly in major tech stocks.
Loe
30. juuli 2026, 19:59 UTC
Jazz Pharmaceuticals shares are higher, reflecting broader market recovery amid significant gains in the technology sector. The stock is near the upper end of its one-month range.
Loe
29. juuli 2026, 18:26 UTC
Jazz Pharmaceuticals PLC is trading higher during Wednesday's session, with fluctuations within a routine range and positioned above its 20-day moving average.
Loe
28. juuli 2026, 23:46 UTC
Jazz Pharmaceuticals PLC shares are higher in after-market trading, recovering from an early low and remaining above the 20-day moving average.
Loe
27. juuli 2026, 19:37 UTC
Jazz Pharmaceuticals PLC is trading higher, recently reaching a new 52-week high amid increased investor interest and significant average volume exceeding $50 million.
Loe
24. juuli 2026, 20:07 UTC
Jazz Pharmaceuticals PLC shares are lower today amid broader market dynamics influenced by recent oil price volatility, despite remaining above its 20-day moving average.
Loe
Võrdlus sarnastega
Hinnamuutus
Jazz Pharmaceuticals PLC Prognoos
Hinnangu Konsensus
By TipRanks
Tugev "osta" hinnang
16 ratings
16
Osta
0
Hoia
0
Müü
Põhineb 16 analüütiku instrumendi Jazz Pharmaceuticals PLC aktsia reitingul - viimase 3 kuu andmed.
Sentiment
By Acuity
Uudiste sentiment
Neutral
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$